drugset / Trial / NCT06732960
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients
Phase 2
Completed
50 enrolled
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Beijing Friendship Hospital · collabJinan Central Hospital · collabShanghai Jiao Tong University Affiliated Sixth People's Hospital · collab
RandomizedSequentialDouble-blindTreatment
Summary
This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.
Timeline
- Start
- 2024-04-21
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efsubaglutide Alfa | Protein / enzyme biologic | 5 mg | Subcutaneous |
| Subject | Efsubaglutide Alfa | Protein / enzyme biologic | 7.5 mg | Subcutaneous |
| Subject | Efsubaglutide Alfa | Protein / enzyme biologic | 10 mg | Subcutaneous |